Effect of ocrelizumab on leptomeningeal inflammation and humoral response to Epstein-Barr virus in multiple sclerosis. A pilot study. uri icon

authors

  • Zivadinov, Robert
  • Dejan Jakimovski MD, PhD
  • Ramanathan, Murali
  • Benedict, Ralph Hb
  • Bergsland, Niels
  • Dwyer, Michael G
  • Weinstock-Guttman, Bianca

publication date

  • January 1, 2022